Argent BioPharma Ltd
Argent BioPharma Limited is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems.
The business
Argent BioPharma Limited is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The Company’s assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The Company’s proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. It focuses on urgent unmet needs in the central nervous system (CNS) and systemic inflammation. Its product pipeline includes CimetrA, CannEpil, CogniCann and others. CannEpil is a refractory epilepsy seizure control treatment. CogniCann is an investigational oral spray developed by the Company to help manage symptoms associated with dementia and Alzheimer’s disease. The Company has a patient base in Australia, the United Kingdom, Brazil, and Ireland.
Small Caps Research
No research on Argent BioPharma Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RGT based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Argent BioPharma Licences CannEpil Globally in US$5.5m Debt-Clearing Transaction
Argent BioPharma inks global CannEpil license with Splash Beverage, US$5.5m upfront debt-clearing, 15% royalty; boosts US growth and potential listing.
Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann
Argent BioPharma (ASX: RGT) has signed a binding term sheet to acquire the key assets of AusCann Group Holdings, a deal designed to expand its clinical pipeline, intellectual property (IP) portfolio, and European presence. The US$15 million scrip-based transaction will see AusCann receive 25 million Argent shares at US$0.60 each, with completion expected in the […]
Argent BioPharma to Supply Cannabinoid Treatment for Drug-Resistant Epilepsy in Slovenia
Argent BioPharma (ASX: RGT) has commenced the supply of a cannabinoid-based active pharmaceutical ingredient (API) to treat refractory (or drug-resistant) epilepsy patients at Slovenia’s largest hospital. The API will be transitioned to routine use at the paediatric clinic within University Medical Centre Ljubljana (UMCL) following a successful pilot program, enabling neurologists to dispense recommended, protocol-aligned […]
Argent BioPharma gains approval for prescription sales of CannEpil epilepsy treatment in Germany
Argent BioPharma’s (ASX: RGT) flagship CannEpil cannabinoid-based therapy for the treatment of refractory (or drug-resistant) epilepsy has been approved for prescription in Germany under a special access scheme. The approval means that doctors can now prescribe the drug to eligible patients, who may also qualify for health insurance coverage depending on the doctor’s recommendation and […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.